MaaT Pharma Balance Sheet Health
Financial Health criteria checks 5/6
MaaT Pharma has a total shareholder equity of €20.5M and total debt of €8.0M, which brings its debt-to-equity ratio to 38.9%. Its total assets and total liabilities are €42.9M and €22.5M respectively.
Key information
38.9%
Debt to equity ratio
€7.97m
Debt
Interest coverage ratio | n/a |
Cash | €24.31m |
Equity | €20.47m |
Total liabilities | €22.47m |
Total assets | €42.93m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MAAT's short term assets (€32.0M) exceed its short term liabilities (€11.5M).
Long Term Liabilities: MAAT's short term assets (€32.0M) exceed its long term liabilities (€10.9M).
Debt to Equity History and Analysis
Debt Level: MAAT has more cash than its total debt.
Reducing Debt: MAAT's debt to equity ratio has reduced from 205% to 38.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MAAT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MAAT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 31% each year